Opus Point Partners Management as of June 30, 2019
Portfolio Holdings for Opus Point Partners Management
Opus Point Partners Management holds 62 positions in its portfolio as reported in the June 2019 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| iShares NASDAQ Biotechnology Index (IBB) | 33.9 | $23M | 210k | 109.11 | |
| Direxion Shs Etf Tr sp biotch bl | 7.3 | $4.9M | 98k | 50.19 | |
| Mettler-Toledo International (MTD) | 4.0 | $2.7M | 3.2k | 839.88 | |
| Illumina (ILMN) | 2.6 | $1.7M | 4.7k | 368.16 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 2.2 | $1.5M | 8.2k | 183.33 | |
| Bristol Myers Squibb (BMY) | 2.2 | $1.5M | 33k | 45.36 | |
| Alexion Pharmaceuticals | 1.9 | $1.3M | 9.9k | 130.96 | |
| Ionis Pharmaceuticals (IONS) | 1.9 | $1.3M | 20k | 64.25 | |
| Proqr Thrapeutics N V shs euro (PRQR) | 1.9 | $1.3M | 139k | 9.10 | |
| Seattle Genetics | 1.8 | $1.2M | 18k | 69.21 | |
| Qiagen Nv | 1.7 | $1.2M | 29k | 40.54 | |
| Uniqure Nv (QURE) | 1.6 | $1.1M | 14k | 78.16 | |
| EXACT Sciences Corporation (EXAS) | 1.5 | $1.0M | 8.5k | 118.00 | |
| Spark Therapeutics | 1.5 | $993k | 9.7k | 102.38 | |
| Alnylam Pharmaceuticals (ALNY) | 1.4 | $969k | 13k | 72.58 | |
| Incyte Corporation (INCY) | 1.3 | $902k | 11k | 84.99 | |
| Immunomedics | 1.3 | $868k | 63k | 13.87 | |
| Sarepta Therapeutics (SRPT) | 1.2 | $813k | 5.4k | 151.88 | |
| BioMarin Pharmaceutical (BMRN) | 1.2 | $805k | 9.4k | 85.64 | |
| Bluebird Bio (BLUE) | 1.1 | $743k | 5.8k | 127.23 | |
| Ascendis Pharma A S (ASND) | 1.1 | $713k | 6.2k | 115.19 | |
| Regeneron Pharmaceuticals (REGN) | 1.0 | $695k | 2.2k | 312.92 | |
| Insmed (INSM) | 1.0 | $690k | 27k | 25.62 | |
| Audentes Therapeutics | 1.0 | $656k | 17k | 37.83 | |
| Blueprint Medicines (BPMC) | 0.9 | $640k | 6.8k | 94.40 | |
| G1 Therapeutics | 0.9 | $639k | 21k | 30.66 | |
| Epizyme | 0.9 | $632k | 50k | 12.55 | |
| Gw Pharmaceuticals Plc ads | 0.9 | $633k | 3.7k | 172.29 | |
| Crispr Therapeutics (CRSP) | 0.9 | $622k | 13k | 47.07 | |
| Arena Pharmaceuticals | 0.8 | $573k | 9.8k | 58.65 | |
| Celgene Corporation | 0.8 | $520k | 5.6k | 92.44 | |
| Macrogenics (MGNX) | 0.8 | $510k | 30k | 16.96 | |
| Global Blood Therapeutics In | 0.7 | $499k | 9.5k | 52.64 | |
| Pacira Pharmaceuticals (PCRX) | 0.7 | $489k | 11k | 43.47 | |
| Biohaven Pharmaceutical Holding | 0.7 | $475k | 11k | 43.77 | |
| Intercept Pharmaceuticals In | 0.7 | $467k | 5.9k | 79.53 | |
| Zogenix | 0.7 | $465k | 9.7k | 47.81 | |
| Intellia Therapeutics (NTLA) | 0.7 | $466k | 29k | 16.36 | |
| Amicus Therapeutics (FOLD) | 0.7 | $458k | 37k | 12.47 | |
| Nektar Therapeutics (NKTR) | 0.7 | $445k | 13k | 35.59 | |
| Deciphera Pharmaceuticals | 0.6 | $420k | 19k | 22.54 | |
| Viking Therapeutics (VKTX) | 0.6 | $402k | 49k | 8.29 | |
| Madrigal Pharmaceuticals (MDGL) | 0.6 | $374k | 3.6k | 104.76 | |
| Fortress Biotech | 0.5 | $351k | 234k | 1.50 | |
| Anaptysbio Inc Common (ANAB) | 0.5 | $345k | 6.1k | 56.41 | |
| Checkpoint Therapeutics | 0.5 | $342k | 113k | 3.03 | |
| Amarin Corporation (AMRN) | 0.5 | $323k | 17k | 19.41 | |
| Ultragenyx Pharmaceutical (RARE) | 0.5 | $322k | 5.1k | 63.59 | |
| Bio-techne Corporation (TECH) | 0.5 | $323k | 1.6k | 208.25 | |
| ACADIA Pharmaceuticals (ACAD) | 0.5 | $320k | 12k | 26.71 | |
| Iqvia Holdings (IQV) | 0.5 | $319k | 2.0k | 160.71 | |
| Charles River Laboratories (CRL) | 0.4 | $300k | 2.1k | 142.05 | |
| Gilead Sciences (GILD) | 0.4 | $276k | 4.1k | 67.61 | |
| Grifols S A Sponsored Adr R (GRFS) | 0.4 | $278k | 13k | 21.07 | |
| Biogen Idec (BIIB) | 0.4 | $263k | 1.1k | 234.19 | |
| Amgen (AMGN) | 0.4 | $257k | 1.4k | 183.97 | |
| Neurocrine Biosciences (NBIX) | 0.4 | $254k | 3.0k | 84.33 | |
| Exelixis (EXEL) | 0.4 | $244k | 11k | 21.33 | |
| Ligand Pharmaceuticals In (LGND) | 0.4 | $241k | 2.1k | 114.16 | |
| Agios Pharmaceuticals (AGIO) | 0.4 | $240k | 4.8k | 49.94 | |
| Fibrogen (FGEN) | 0.3 | $221k | 4.9k | 45.26 | |
| Recro Pharma | 0.2 | $115k | 11k | 10.13 |
